A selective decoy–doxorubicin complex for targeted co-delivery, STAT3 probing and synergistic anti-cancer effect
A novel selective decoy oligodeoxynucleotide (dODN)–doxorubicin (DOX) complex is reported for cancer theranostics.
2020 ◽
Vol 20
(11)
◽
pp. 1340-1351
◽
Keyword(s):
MoS2–ZnO nanocomposites as highly functional agents for anti-angiogenic and anti-cancer theranostics
2018 ◽
Vol 6
(19)
◽
pp. 3048-3057
◽
Keyword(s):
2018 ◽
Vol 110
◽
pp. 392-398
◽
Keyword(s):
2020 ◽